BHCM
FDMT icon

Brevan Howard Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Brevan Howard Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
+176,850
New +$1.72M 0.02% 655
2025
Q4 		– Sell
-16,400
Closed -$143K – 1955
2025
Q3 		$143K Buy
+16,400
New +$98K ﹤0.01% 1821
2025
Q2 		– Sell
-14,800
Closed -$47.8K – 1891
2025
Q1 		$47.8K Buy
+14,800
New +$69.7K ﹤0.01% 1090
2024
Q3 		– Sell
-11,079
Closed -$233K – 1232
2024
Q2 		$233K Buy
+11,079
New +$278K ﹤0.01% 852

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Brevan Howard Capital Management's FDMT Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 176,850 shares worth $2.35M. The stake represents 0.02% of the portfolio and ranks #655 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in FDMT as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in FDMT in Q2 2024 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Brevan Howard Capital Management held 176,850 shares of 4D Molecular Therapeutics worth $2.35M as of Q2 2026.
  • 4D Molecular Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • 4D Molecular Therapeutics made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #655 holding.
  • Brevan Howard Capital Management first reported a position in 4D Molecular Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.